Profile data is unavailable for this security.

About the company

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

  • Revenue in JPY (TTM)2.88tn
  • Net income in JPY15.64bn
  • Incorporated1925
  • Employees49.58k
  • Location
    Takeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
  • Phone+81 332782111
  • Fax+81 332782000
  • Websitehttps://www.takeda.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Merck KGaA1.88tn137.26bn1.85tn54.04k45.272.915.270.98022.627.9635.9841.760.40251.944.86302,786.502.964.543.905.9863.1366.097.3511.031.085.400.40839.902.205.98-57.97-2.2814.485.64
Shionogi & Co Ltd356.40bn126.48bn2.13tn5.23k16.593.0414.695.98405.18405.181,141.932,208.950.46791.447.6668,105,300.0016.6113.2118.4315.0783.7177.7235.4926.766.31--0.001126.565.534.6521.9526.73-12.1115.36
Alexion Pharmaceuticals, Inc.516.87bn148.51bn2.58tn2.66k17.722.2813.565.006.046.5321.0746.850.33050.7474.671,782,982.009.503.2410.253.5192.0490.4328.7310.963.4523.890.20130.0016.3421.64-95.69-39.1548.67--
Otsuka Holdings Co Ltd1.37tn116.33bn2.70tn32.94k23.281.5214.231.97208.24208.242,532.433,189.110.52892.703.7441,677,970.004.63--5.68--67.28--8.75--1.95--0.1572--4.20---26.67------
Astellas Pharma Inc1.31tn246.93bn3.57tn16.24k14.552.7511.522.72129.85129.85689.28687.450.67741.933.9880,633,010.0012.7710.3416.8213.4378.0675.9018.8514.301.46--0.113537.460.46392.7634.9719.59-1.477.07
Chugai Pharmaceutical Co Ltd662.20bn139.54bn5.95tn7.43k41.777.16--8.99254.58254.581,208.131,485.300.69121.623.5889,100,910.0014.578.4017.359.9359.2552.3221.0813.072.80--0.0050.538.536.4827.2012.6939.019.86
Takeda Pharmaceutical Co Ltd2.88tn15.64bn6.73tn49.58k133.081.3712.192.3432.1032.102,130.243,123.560.33541.864.6458,025,380.000.18431.360.21551.7765.2269.830.54943.830.93820.47140.5078226.3318.454.39-41.610.458611.300.00
Bayer AG5.28tn-179.85bn8.94tn104.71k--1.5320.751.69-1.53-1.3044.6949.290.33571.733.74374,852.60-1.144.12-1.395.2857.4258.83-3.398.160.88264.110.486969.6713.05-0.286-47.83-11.873.756.26
Novartis AG5.41tn786.99bn26.34tn109.00k30.804.1218.834.873.024.9320.7222.560.38292.216.04385,292.905.576.817.138.4170.9066.5514.5517.420.728357.900.364174.616.050.170265.026.53-0.13660.9933
Data as of Jan 29 2020. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

20.56%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 30 Sep 201954.77m3.47%
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 15 Mar 201953.21m3.38%
BlackRock Fund Advisorsas of 15 Jan 201949.61m3.15%
The Vanguard Group, Inc.as of 09 Oct 201830.96m1.96%
Nikko Asset Management Co., Ltd.as of 15 Mar 201925.19m1.60%
Capital Research & Management Co. (World Investors)as of 31 Dec 201924.95m1.58%
State Street Global Advisors Ltd.as of 07 Jan 201924.73m1.57%
Mondrian Investment Partners Ltd.as of 08 Jan 201921.44m1.36%
Wellington Management Co. LLPas of 08 Jan 201920.29m1.29%
Templeton Global Advisors Ltd.as of 30 Nov 201919.01m1.21%
More ▼
Data from 25 Jul 2019 - 23 Jan 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.